ADOPTION OF ORAL DISEASE MODIFYING TREATMENTS TO MANAGE PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS FROM 2011-2013 IN THE UNITED STATES
Author(s)
Narayanan S1, O'Meara P2, White J3, Chan J3, Gabriele S3, Hautamaki E1
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, London, UK
OBJECTIVES: New oral Disease Modifying Treatments (DMTs) for Relapsing Remitting Multiple Sclerosis (RRMS) were recently introduced in the US. The objective of this study was to assess trends in adoption of oral DMTs among RRMS patients in the US. METHODS: A multi-center retrospective chart-review study of RRMS patients was conducted in the US in 4Q2011, 4Q2012, 2Q2013, and 4Q2013 to collect de-identified data on diagnosis, clinical status, and treatment patterns. Neurologists were screened for duration of practice (≥3yrs) and patient volume (≥15 MS patients/mo) and recruited from a large panel to be geographically representative. Medical charts of next 10 consecutive MS patients were abstracted by each neurologist. RRMS patients taking oral, injectable, or infusible DMTs were analyzed. RESULTS:
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PND80
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Neurological Disorders